Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial
Jakubowiak, Andrzej J., Griffith, Kent A., Reece, Donna E., Hofmeister, Craig C., Lonial, Sagar, Zimmerman, Todd M., Campagnaro, Erica L., Schlossman, Robert L., Laubach, Jacob P., Raje, Noopur S., Anderson, Tara, Mietzel, Melissa A., Harvey, Colleen K., Wear, Sandra M., Barrickman, Jennifer C., Tendler, Craig L., Esseltine, Dixie-Lee, Kelley, Susan L., Kaminski, Mark S., Anderson, Kenneth C., Richardson, Paul G.
Published in Blood (21.07.2011)
Published in Blood (21.07.2011)
Get full text
Journal Article
An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma
Vij, Ravi, Wang, Michael, Kaufman, Jonathan L., Lonial, Sagar, Jakubowiak, Andrzej J., Stewart, A. Keith, Kukreti, Vishal, Jagannath, Sundar, McDonagh, Kevin T., Alsina, Melissa, Bahlis, Nizar J., Reu, Frederic J., Gabrail, Nashat Y., Belch, Andrew, Matous, Jeffrey V., Lee, Peter, Rosen, Peter, Sebag, Michael, Vesole, David H., Kunkel, Lori A., Wear, Sandra M., Wong, Alvin F., Orlowski, Robert Z., Siegel, David S.
Published in Blood (14.06.2012)
Published in Blood (14.06.2012)
Get full text
Journal Article
Final Results of a Frontline Phase 1/2 Study of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (CRd) in Multiple Myeloma (MM)
Jakubowiak, Andrzej J, Dytfeld, Dominik, Jagannath, Sundar, Vesole, David H., Anderson, Tara B., Nordgren, Brian K., Detweiler-Short, Kristen, Lebovic, Daniel, Stockerl-Goldstein, Keith E., Griffith, Kent A., Jobkar, Terri L., Durecki, Diane E, Wear, Sandra M., Ott, Robert F, Al-Zoubi, Ammar, Mietzel, Melissa A, Hussein, M, Couriel, Daniel, Leveque, Joseph A, Vij, Ravi
Published in Blood (18.11.2011)
Published in Blood (18.11.2011)
Get full text
Journal Article
Vantage 095: Vorinostat in Combination with Bortezomib in Salvage Multiple Myeloma Patients: Final Study Results of a Global Phase 2b Trial
Siegel, David S., Dimopoulos, Meletios Athanasios, Yoon, Sung-Soo, Laubach, Jacob P., Kaufman, Jonathan L., Goldschmidt, Hartmut, Reece, Donna E., Leleu, Xavier, Durrant, Simon, Offner, Fritz C., Cavo, Michele, Nagler, Arnon, Jagannath, Sundar, Graef, Thorsten, Houp, Jennifer, Sun, Linda, Howe, Jason, Wear, Sandra M., Anderson, Kenneth C.
Published in Blood (18.11.2011)
Published in Blood (18.11.2011)
Get full text
Journal Article
Unfavorable Cytogenetic Characteristics Do Not Adversely Impact Response Rates in Patients with Relapsed and/or Refractory Multiple Myeloma Treated with Single-Agent Carfilzomib on the 003 (A1) Study
Jakubowiak, Andrzej J, Siegel, David S., Singhal, Seema, Martin, Thomas, Lonial, Sagar, Kukreti, Vishal, Bahlis, Nizar, Chanan-Khan, Asher Alban, Alsina, Melissa, Somlo, George, Buadi, Francis K, Reu, Frederic J., Song, Kevin W., Kunkel, Lori, Wear, Sandra M., Wong, Alvin F., Orlowski, Robert Z., Stewart, A. Keith, Jagannath, Sundar, Wang, Luhua
Published in Blood (18.11.2011)
Published in Blood (18.11.2011)
Get full text
Journal Article
The Multiple Myeloma Research Consortium (MMRC): Accelerated Start up and Accrual Metrics Speeds Drug Development
Wear, Sandra M., Richardson, Paul G., Revta, Carolyn, Vij, Ravi, Fiala, Mark, Lonial, Sagar, Mitchell, Alaina R., Siegel, David S., Aleman, Adolfo, Jakubowiak, Andrzej J, Durecki, Diane E, Reece, Donna E., Gul, Engin, Chari, Ajai, Jagannath, Sundar, La, Lisa, Hofmeister, Craig C., Bowers, Mindy A, Stewart, A. Keith, Hagerty, Rachel, Wolf, Jeffrey L., Pelle-Day, Geraldine, Krishnan, Amrita, Duarte, Lupe, Zimmerman, Todd M., Larsen, Daniel, Kumar, Shaji, Birgin, Ann, Raje, Noopur S., Roy, Vivek, Maharaj, Michele, Fay, Joseph W., Messing, Tracey, Ott, Robert F, Tasca, Leah, Anderson, Kenneth C., Giusti, Kathy
Published in Blood (18.11.2011)
Published in Blood (18.11.2011)
Get full text
Journal Article